Week 1- Respiratory Flashcards

(50 cards)

1
Q

Physiology - Compliance

A

This is an indication of how well the chest wall and lungs can expand and collapse. If the patient has decreased compliance, it is more difficult to inflate the lungs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Physiology - Resistance

A

This relates to the size of the airway. The resistance of the airway increases when the diameter of the airway decreases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Physiology- V/Q mismatch

A

When there are issues with ventilation and perfusion, the diffusion of gases is altered. This is called a V/Q mismatch.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Acute Pulmonary Oedema (APO)

A

Acute Pulmonary Oedema (APO) is a life threatening condition, caused by excess fluid in the lungs. It can be a complication observed in deteriorating patients who have a history of heart failure. That said, there are also other acute causes of APO.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Our lungs are usually kept dry by a combination of the following normal processes and forces, such as:

A

Lymphatic drainage involves various pressures, including hydrostatic, capillary oncotic, capillary permeability, and the presence of surfactants. These pressures help push fluid out of vessels, maintain capillary permeability, and prevent large molecules from entering alveoli.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cardiogenic APO

A

one type of APO and can have heart failure as one of its causes. As the pressures in the heart increase cardiac output (CO) is decreased, as the ventricle must pump against an increased systemic vascular resistance (SVR).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cardiogenic APO occurs when

A

Blood entering the left atrium from the lungs exceeds that leaving the left ventricle, causing increased pulmonary vein pressure and pulmonary capillary hydrostatic pressure. This leads to net filtration of fluid into interstitial spaces and alveoli.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Summary pathophysiology of APO

A
  1. Abnormal accumulation of fluid in the lung tissue, the alveolar space, or both
  2. Impaired gas exchange and decreased lung compliance
  3. Sudden onset of symptoms
  4. Requires immediate emergency management
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cardiac (cardiogenic) APO common causes:

A
  • Heart disease/left ventricular dysfunction
  • AMI (Acute Myocardial Infarction/ heart attack)
  • Acute dysrhythmia (any abnormality of physiologic rhythm, either atrial or ventricular)
  • Valvular insufficiency (cardiac disease characterised by the failure of the cardiac valves to close perfectly, resulting in blood flowing in the opposite direction; thereby, causing regurgitation or leakage)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Non-cardiac (non-cardiogenic) APO common causes:

A
  • Capillary injury
  • Obstruction of lymphatic system
  • Blood transfusion/fluid overload
  • Acute lung injury
  • High altitude
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Clinical Manifestions

A
  • Sudden onset of extreme breathlessness
  • Hypertension (because of hyper-adrenergic state)
  • Tachypnoea
  • Hypotension = severe LVF and cardiogenic shock
  • Chest auscultation – crackles
  • Diaphoresis
  • Cough
  • Raised JVP
  • Pink frothy sputum present if alveoli injured
  • Anxiety and agitation
  • Cyanosis (late sign)
  • Confusion
  • Tachycardia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

APO think

A

Why would the patient develop tachycardia? Well, the patient who is experiencing cardiogenic APO has a failing left ventricle. The left ventricle is unable to pump effectively and eject blood forwards (into the aorta). This means the patient has a reduction in their cardiac output (CO). If you think back to the equation cardiac output = stroke volume x heart rate (CO = SV x HR), then you can see that the heart rate needs to increase in order to maintain the cardiac output. This is one of the ways the body can compensate for a drop in cardiac output and explains why tachycardia occurs in cardiogenic APO.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

APO Assessment & Management: airway

A

Partial obstruction of the lower airway (frothy sputum), Cough, Words/ short sentences. Resulting in need for suction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

APO Assessment & Management: breathing

A

Shortness of breath, Tachypnoea, Increased work of breathing (WOB), Hypoxia, Adventitious breath sounds (crackles). Resulting in need to apply oxygen and postion patient upright

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

APO Assessment & Management: circulation

A

Hypertensive, Hypotension (cardiogenic shock), Tachycardia, Arrhythmia (cause), Pallor, cool and clammy skin. Check vital signs frequently, assess pain, IVC, pathology (VBG), ECG & cardiac monitoring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

APO Assessment & Management: disability

A

Altered conscious state, confusion, Restless, anxious. Check GCS frequently, BSL, IDC and provide reassurance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

APO Management

A
  • Continuous reassessment: ABCD
  • Respiratory: manage hypoxia
    • Oxygen: maintain saturations
      >94% (88-92% in COPD)
    • Ventilatory support: Non-Invasive
      Positive Pressure Ventilation
      (NIPPV)
  • Cardiac: reduce preload and afterload
    • Nitrates (GTN): Sublingually or
      intravenous infusion
    • Diuretics (Furosemide):
      Controversial. IV rather than oral
    • Morphine: Lack of good evidence
      to support efficacy
  • Aetiology: Treat underlying cause
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

NIPPV

A
  • Ventilatory support for a spontaneously breathing patient
  • Improves lung compliance
  • Reduces V/Q mismatch
  • Lowers intubation rates and reduces mortality rate
  • Less expensive than intubation
  • Fewer complications than invasive mechanical ventilation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Indications for NIPPV

A
  • APO (cardiogenic)
  • COPD acute exacerbation
  • Moderate to severe respiratory distress
  • Pneumonia
  • Atelectasis
  • Dyspnoea
  • Accessory muscle use
  • SpO2 less than 90%
  • Increased respiratory rate (>24 for COPD)
  • Respiratory acidosis (pH < 7.35, PaCO2 > than 45 mmHg)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Contraindications for NIPPV

A
  • Uncooperative/ extreme anxiety/ depressed level of consciousness
  • Unable to protect airway/ risk of aspiration (impaired swallowing or cough)
  • Poor respiratory drive (Head injury)
  • Haemodynamic instability
  • Myocardial ischaemia/ unstable angina
  • Copious respiratory secretions
  • Difficulty fitting mask (Facial Trauma/ burns/ abnormalities)
  • Pneumothorax
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Complications of NIPPV

A
  • Hypotension (↑ intrathoracic pressure, ↓ venous return, ↓ CO)
  • Myocardial Ischaemia (↑ intrathoracic pressure, ↓ coronary perfusion)
  • Altered conscious state (↓ CO, ↓ Cerebral perfusion)
  • Risk of aspiration (vomiting)
  • Gastric distension (swallowing air)
  • Barotrauma
  • Pneumothorax (↑ positive pressure)
  • Pressure sores (mask)
22
Q

Nursing Management of NIPPV
Response

A
  • Monitor GCS for decrease Airway
  • Monitor for patency
  • Observe for secretions
  • Check equipment including suction
  • Aspiration risk
23
Q

Nursing Management of NIPPV
Breathing

A
  • Monitor RR / WOB / SaO2 / ABGs
  • Assess speech pattern
    • Talking in sentences / words / nil
  • Auscultate chest
  • Nurse in Fowlers position
  • Repeated focussed respiratory assessment
  • Monitor NIPPV delivery settings
    • FiO2, PEEP, IPAP, flow rate
24
Q

Nursing Management of NIPPV
Circulation

A
  • Monitor HR
  • Monitor BP
  • Cardiac monitor
  • ECG
  • Monitor urine output
25
Nursing Management of NIPPV Disability
* 1:1 nurse/ patient ratio * Monitor GCS * Assess fitting of face mask * Pressure area care * Temperature * Monitor for nausea
26
Pulmonary Embolism (PE)
a life threatening condition where a blockage occurs in one or more of the pulmonary arteries. Pulmonary embolism is a partial or complete occlusion of a pulmonary artery, or one of its branches, by an embolism. The obstruction can be the result of a blood clot, air or fat.
27
PE: There is a release of neurohumoral substances and inflammatory mediators which can result in:
* Vasoconstriction of the pulmonary capillaries * Increased pulmonary artery pressure which may lead to right heart failure * Increased dead space as perfusion is decreased (V/Q mismatch) * Decreased surfactant * Hypoxaemia * Arrhythmias * Decreased cardiac output, shock and death
28
Summary of pathophysiology of PE:
* Blockage of a pulmonary blood vessel, by blood borne material originating from the venous system * Prevents gas exchange, creates V/ Q mismatch, infarction lung tissue * Different classifications (massive/ Nonmassive-low risk) Symptoms * Variable, depending on size of clot * Non-specific
29
Risk factors for PE
* Blood clotting from venous stasis * Hypercoagulability * Endothelial injury
30
Clinical manifestations of PE
* Sudden onset pleuritic chest pain * Tachypnoea * Unexplained anxiety * Dyspnoea * Tachycardia * Assess for DVT
31
Investigations for PE
* Chest x-ray -atelectasis * CTPA * ABG - hypoxaemia * CT * ECG – right heart strain
32
Types & Causes of PE
* Thrombus: most commonly lower limbs * Fat: orthopaedic surgery/ long bone trauma * Air: CVC insertion, insufflation of air proceduresLaparoscopy * Amniotic fluid: birthing process * Septic: bacterial invasion of the thrombus
33
Diagnosis of PE
Presentation can be inconsistent so diagnosis starts with an estimation of probability: * Clinical presentation * Obtain history * Venous thromboembolism (VTE) risk assessment * Investigations * D-dimer: not diagnostic * Chest XR: exclude other causes, NAD, atelectasis * Ventilation-perfusion (VQ scan): common, renal impairment, pregnancy * CT Pulmonary Angiogram (CTPA): accurate, specialised staff, radiation risk/ contrast * Lower leg ultrasound: diagnose/ exclude DVT
34
PE Assessment and Management AIRWAY
* Patent/ obstructed (unconscious). DRSABCD/ airway support
35
PE Assessment and Management BREATHING
* Dyspnoea (V/Q mismatch, hypoxaemia) * Tachypnoea * ↑ Work of breathing (atelectasis) * Hypoxaemia/ Hypocapnia * Auscultation * Haemoptysis O2 to maintain saturations, position patient for comfort, deep breathing reduce atelectasis, limit activity
36
PE Assessment and Management CIRCULATION
* Hypotension (↓CO) * Tachycardia (compensation) * ↓ Capillary refill time * Pale, cool, clammy Vital signs, ECG, cardiac monitoring, IVC, pathology (ABGs, coagulation, D-dimer, Troponin), IVT if shock present
37
PE Assessment and Management DISABILITY
* Anxious/ confused * Chest pain (sudden/ pleuritic) * Signs of DVT (unilateral leg pain etc.) Check GCS, PQRST, provide reassurance, pain relief (prevent hypoventilation), rest, preparation for further investigations
38
Treatment — Anticoagulation
Prevents the formation of new thrombi and allows endogenous fibrinolysis to take effect on the embolus Possible contraindications: * Severe thrombocytopenia * Active bleeding * History of haemorrhagic stroke * Severe hepatic disease * Bacterial endocarditis
39
Anticoagulation: Unfractionated Heparin (Heparin Sodium):
* IV infusion (+ loading dose) * Commenced immediately x 3-5 days * Dose titrated to APTT as per hospital protocol Adverse effects: * Bleeding * Bruising * Hyperkalaemia * Heparin induced thrombocytopenia * Allergic reactions
40
Anticoagulation: Low molecular weight heparin (Enoxaparin):
* Subcutaneous, therapeutic dose (mg/kg) cf prophylactic dose * Haemodynamically stable PE * Less frequent monitoring (APTT/ PT usually not increased)
41
Anticoagulation: Vitamin K antagonist (Warfarin):
* Oral x 3-6 months * Long time for therapeutic effect (overlap with Heparin therapy) * INR monitoring * Recurring PE may require lifelong treatment
42
Anticoagulation: Direct oral anticoagulant (DOAC) (Rivaroxaban):
* Quick onset of action * APTT/ PT monitoring not required
43
Treatment — Thrombolysis
Accelerates clot lysis (‘clot buster’) to restore pulmonary reperfusion * Use in massive PE/ haemodynamically unstable * Time critical (4 hours) * High risk of major haemorrhage/ uncontrolled bleeding * Essential invasive procedures only * Contraindications * Active bleeding/ bleeding tendency * Recent stroke (2 months) * Recent surgery (10 days) * Recent head trauma (3 months) * Recent labour/delivery * Severe uncontrolled hypertension
44
Thrombolysis: Thrombolytic (Alteplase):
* IV infusion (+ anticoagulation follow up) * Massive PE/ haemodynamically unstable * Produces local fibrinolysis * Peak plasma time 20-40 minutes
45
Treatment — Embolectomy
* Life threatening PE * Haemodynamically unstable * Thrombolysis contraindicated * Approach * Surgical embolectomy (thorocotomy) * Transvenous catheter * Inferior Vena Cava filter * High mortality rate of 30% * Risks associated with any surgery
46
Nursing Considerations
VTE prevention is a Clinical Care Standard (Australian Commission on Safety and Quality in Healthcare) * Assessment and documentation of VTE risk * Identify risk factors * Venous stasis (reduced mobility, obesity, dehydration, AF) * Hypercoaguable states (surgery, oestrogen replacement, oral contraceptive pill, cancer) * Vessel damage (smoking, ↑ cholesterol, varicose veins, venepuncture) * Development of a VTE prevention plan * Chemical, monitor effects of treatment * Mechanical (as appropriate) * Inform and partner with patients * Patient education of risk factors, for VTE prevention
47
Nasal prongs
1-4L Oxygen concentration: 22-35% Risks: pressure injury to nares and ears. Dry nasal mucosa Nursing care: check pressure areas, regular mouth and lips care, monitor for epistaxis
48
Hudson mask
5-10L Oxygen concentration: 35-60% Risks: pressure injury to bridge of nose and ears. Dry nasal mucosa. Non- compliance, claustrophobia, aspiration of vomit Nursing care: check pressure areas, regular mouth and lips care, monitor for epistaxis, min flow of 4L, ensure device is in place
49
Non-rebreather face mask
10-15L Oxygen concentration: >60% Risks: pressure injury to nares and ears. Dry nasal mucosa, suffocation if inadequate oxygen in bag Nursing care: check pressure areas, regular mouth and lips care, monitor for epistaxis, ensure bag is inflated before attaching to patient, do not leave patient alone
50
Humidified High-flow Oxygen Delivery
High flow oxygen delivery systems deliver oxygen at rates higher than traditional oxygen delivery devices; up to 60 L/minute compared to 15L/ minute, and because they deliver a more reliable FiO2 and are generally well tolerated by patients, they are increasingly being used in the clinical setting.